Concord Biotech To Consider Bonus Share Proposal At September 23 Board Meeting

Board meeting scheduled: September 23, 2026

Agenda: Consider declaration of bonus equity shares

Reader Takeaway: Potential shareholder reward; bonus ratio and approvals remain pending.

What just happened

Concord Biotech Ltd informed the stock exchanges that its Board of Directors will meet on September 23, 2026.

The key agenda is to consider and approve a proposal for the issue of bonus equity shares to existing shareholders.

The filing makes it clear that the proposal is presently under board consideration. Any bonus issue will remain subject to the required statutory and shareholder approvals.

Why this matters

A bonus issue increases the number of shares held by existing shareholders without requiring additional investment from them.

While it does not change the company's overall market value by itself, a bonus issue can improve trading liquidity by increasing the number of shares available in the market.

The most important details for investors, including the bonus ratio and record date, have not yet been announced.

What changes now

The company has closed its trading window from September 19, 2026.

The trading restriction applies to designated persons and their immediate relatives and will remain in force until 48 hours after the board meeting outcome is disclosed. According to the filing, the trading window is scheduled to reopen on September 26, 2026.

What to track next

Investors should monitor:

• Whether the board approves the bonus proposal.
• The announced bonus share ratio, if approved.
• The record date for determining eligible shareholders.
• Any requirement for shareholder approval before implementation.

The September 23 board meeting outcome will determine the next steps for the proposed corporate action.